Opexa Therapeutics Inc (OPXA.PH)
9 Dec 2016
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|52||2016||President, Chief Executive Officer, Acting Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, Director|
- BRIEF-Opexa Therapeutics receives notice from Ares Trading S.A. Unit of Merck Serono
- BRIEF-Opexa Therapeutics reports qtrly loss per share of $0.28
- BRIEF-Opexa Therapeutics qtrly loss per share $0.28
- BRIEF-Opexa Therapeutics announced workforce cut of about 40 pct on Nov. 2 - SEC Filing
- BRIEF-Opexa Therapeutics says failed in mid-stage study